carbon monoxide and Alveolitis, Fibrosing studies

Carbon Monoxide: Carbon monoxide (CO). A poisonous colorless, odorless, tasteless gas. It combines with hemoglobin to form carboxyhemoglobin, which has no oxygen carrying capacity. The resultant oxygen deprivation causes headache, dizziness, decreased pulse and respiratory rates, unconsciousness, and death. (From Merck Index, 11th ed)
carbon monoxide : A one-carbon compound in which the carbon is joined only to a single oxygen. It is a colourless, odourless, tasteless, toxic gas.

Research Excerpts

Excerpt	Relevance	Reference
"Our study shows that amiodarone can be safely used, with an acceptable pulmonary toxicity, in patients with heart failure."	9.08	Pulmonary effect of amiodarone in patients with heart failure. The Congestive Heart Failure-Survival Trial of Antiarrhythmic Therapy (CHF-STAT) Investigators (Veterans Affairs Cooperative Study No. 320). ( Deedwania, PC; Fisher, SG; Fletcher, RD; Rohatgi, P; Singh, BN; Singh, SN, 1997)
" The potential of CO-releasing molecules (CORMs), substances that release CO (Carbon monoxide) within animal tissues, for treating paraquat-induced ROS generation and inflammation is investigated here."	8.02	The effects of carbon monoxide releasing molecules on paraquat-induced pulmonary interstitial inflammation and fibrosis. ( Chang, CY; Cheng, CH; Chiu, HY; Chuu, JJ; Huang, KC; Li, JC; Lin, LS; Wang, SM; Yeh, CH, 2021)
"In an attempt to understand better the potential role of the T cell in the pathogenesis of pulmonary fibrosis (PF) due to sulfur mustard gas inhalation, this study was designed to analyze bronchoalveolar lavage (BAL) lymphocyte subsets and to determine the ratio of CD4 to CD8 lymphocytes in BAL fluid."	7.74	Increased in CD8 T lymphocytes in the BAL fluid of patients with sulfur mustard gas-induced pulmonary fibrosis. ( Emad, A; Emad, Y, 2007)
"Carbon monoxide (CO) has potent anti-inflammatory and anti-oxidant effects."	5.40	Carbon monoxide-bound hemoglobin-vesicles for the treatment of bleomycin-induced pulmonary fibrosis. ( Horinouchi, H; Kobayashi, K; Maruyama, T; Nagao, S; Otagiri, M; Sakai, H; Taguchi, K; Tanaka, R; Watanabe, H, 2014)
"The amiodarone-treated animals showed a significant reduction in the coefficient of diffusion (kCO) and a significant increase in lung hydroxyproline levels as compared to the control group."	5.29	Amiodarone-induced pulmonary fibrosis in Fischer 344 rats. ( Gairola, CG; Lai, YL; Reinhart, PG, 1996)
"Our study shows that amiodarone can be safely used, with an acceptable pulmonary toxicity, in patients with heart failure."	5.08	Pulmonary effect of amiodarone in patients with heart failure. The Congestive Heart Failure-Survival Trial of Antiarrhythmic Therapy (CHF-STAT) Investigators (Veterans Affairs Cooperative Study No. 320). ( Deedwania, PC; Fisher, SG; Fletcher, RD; Rohatgi, P; Singh, BN; Singh, SN, 1997)
" The potential of CO-releasing molecules (CORMs), substances that release CO (Carbon monoxide) within animal tissues, for treating paraquat-induced ROS generation and inflammation is investigated here."	4.02	The effects of carbon monoxide releasing molecules on paraquat-induced pulmonary interstitial inflammation and fibrosis. ( Chang, CY; Cheng, CH; Chiu, HY; Chuu, JJ; Huang, KC; Li, JC; Lin, LS; Wang, SM; Yeh, CH, 2021)
"Lung diffusing capacity for carbon monoxide (DLCO) is decreased in both usual interstitial pneumonia-idiopathic pulmonary fibrosis (UIP-IPF) and nonspecific interstitial pneumonia (NSIP), but is moderately related to computed tomography (CT)-determined fibrotic changes."	3.83	Lung diffusing capacity for nitric oxide as a marker of fibrotic changes in idiopathic interstitial pneumonias. ( Barisione, G; Baroffio, M; Brusasco, C; Brusasco, V; Garlaschi, A, 2016)
" SSc patients with high GDF-15 levels (≥1000 pg/ml) had pulmonary fibrosis, decreased vital capacity, and decreased diffusion capacity for carbon monoxide more often than those with low GDF-15 levels (<1000 pg/ml)."	3.78	Clinical significance of serum growth differentiation factor-15 levels in systemic sclerosis: association with disease severity. ( Asano, Y; Kadono, T; Sato, S; Sugaya, M; Tada, Y; Yanaba, K, 2012)
"In an attempt to understand better the potential role of the T cell in the pathogenesis of pulmonary fibrosis (PF) due to sulfur mustard gas inhalation, this study was designed to analyze bronchoalveolar lavage (BAL) lymphocyte subsets and to determine the ratio of CD4 to CD8 lymphocytes in BAL fluid."	3.74	Increased in CD8 T lymphocytes in the BAL fluid of patients with sulfur mustard gas-induced pulmonary fibrosis. ( Emad, A; Emad, Y, 2007)
"Diffusion capacity for carbon monoxide of the lung (DLCO) before-and-after exercise test and 5 routine pulmonary function tests were conducted in 16 patients with diffuse pulmonary fibrosis (DPF), 19 patients with interstitial pneumonia (IP), 17 patients with COPD, and 22 normal subjects."	3.69	[Diagnostic value of exercise diffusion capacity test on diffuse pulmonary fibrosis]. ( He, T; Luo, Y; Yuan, Y; Zeng, J, 1996)
"Extent of systemic sclerosis (SSc)-related interstitial lung disease (ILD) assessed from thoracic high-resolution CT (HRCT) predicts disease course, mortality and treatment response."	2.82	Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis. ( Clements, P; Elashoff, R; Furst, D; Goldin, J; Khanna, D; Kim, HJ; Kleerup, E; Roth, MD; Tashkin, DP; Tseng, CH; Volkmann, ER, 2016)
" Patients in the treatment group took ambroxol orally at a dosage of 90 mg, three times per day for 3 months from the beginning of radiotherapy."	2.75	The protective effects of ambroxol on radiation lung injury and influence on production of transforming growth factor beta1 and tumor necrosis factor alpha. ( Dai, M; Mao, WD; Shen, WS; Shu, ZQ; Xi, L; Xia, DH; Xv, C; Yang, HZ, 2010)
"A nonsignificant reduction in disease progression was seen in several physiologic, functional, and quality-of-life endpoints among subjects receiving etanercept."	2.73	Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. ( Brown, KK; Costabel, U; Cottin, V; du Bois, RM; Fatenejad, S; Khandker, RK; Lasky, JA; McDermott, L; Raghu, G; Thomeer, M; Utz, JP, 2008)
"Pulmonary fibrosis in systemic sclerosis (SSc) is thought to be the consequence of interstitial inflammation."	2.73	Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis: experience in one centre. ( Beretta, L; Caronni, M; Origgi, L; Ponti, A; Raimondi, M; Scorza, R; Viscuso, T, 2007)
"In 20 patients with bronchial asthma the Hb-CO concentration decreased after 3 weeks of treatment with oral glucocorticoids (p<0."	2.70	Increased blood carboxyhaemoglobin concentrations in inflammatory pulmonary diseases. ( Ohrui, T; Sasaki, H; Yamaya, M; Yanai, M; Yasuda, H, 2002)
"Ten patients with fibrosing alveolitis were treated in a simple random design initially with either a high dose of methylprednisolone (5 patients) or a conventional dose of prednisolone (5 patients) followed by a maintenance dose of 30 mg prednisolone daily."	2.66	High-dose intravenous methylprednisolone pulse therapy as initial treatment in cryptogenic fibrosing alveolitis. A pilot study. ( Bergmann, A; Frøland, SS; Gulsvik, A; Kjelsberg, F; Rootwelt, K; Vale, JR, 1986)
"Combined pulmonary fibrosis and emphysema (CPFE) syndrome is a rare disease characterized with shortness of breath, upper lobe emphysema, lower lobe fibrosis and impairment of gas exchange."	2.52	[A newly-defined entity: combined pulmonary fibrosis and emphysema syndrome]. ( Özçelik, N; Özsu, S, 2015)
"Idiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease with limited therapeutic options."	1.72	Tartrate-resistant acid phosphatase 5 promotes pulmonary fibrosis by modulating β-catenin signaling. ( Deng, Y; Hu, Y; Liu, J; Wang, Q; Wang, Y; Xiong, W; Xu, Y; Yu, J; Zhang, L; Zhou, Q, 2022)
"Carbon monoxide (CO) has potent anti-inflammatory and anti-oxidant effects."	1.40	Carbon monoxide-bound hemoglobin-vesicles for the treatment of bleomycin-induced pulmonary fibrosis. ( Horinouchi, H; Kobayashi, K; Maruyama, T; Nagao, S; Otagiri, M; Sakai, H; Taguchi, K; Tanaka, R; Watanabe, H, 2014)
"A subgroup of patients with idiopathic pulmonary arterial hypertension (IPAH) has severely reduced diffusing capacity of the lung for carbon monoxide (DLCO) and poor prognosis."	1.39	Severely reduced diffusion capacity in idiopathic pulmonary arterial hypertension: patient characteristics and treatment responses. ( Bogaard, HJ; Boonstra, A; de Man, FS; Groepenhoff, H; Grünberg, K; Leter, EM; Nossent, EJ; Trip, P; van den Berk, IA; Vonk-Noordegraaf, A; Westerhof, N, 2013)
"More than 80% of patients with systemic sclerosis (SSc) develop lung involvement, most commonly interstitial pneumonia (IP)."	1.38	The pulmonary fibrosis-associated MUC5B promoter polymorphism does not influence the development of interstitial pneumonia in systemic sclerosis. ( Carns, M; Fingerlin, TE; Hinchcliff, ME; Murphy, E; Peljto, AL; Podlusky, S; Schwartz, DA; Schwarz, M; Steele, MP; Varga, J, 2012)
"Sarcoidosis is a systemic granulomatous disease with predominant manifestation in the lungs, often presenting as interstitial lung disease."	1.36	Impaired lung compliance and DL,CO but no restrictive ventilatory defect in sarcoidosis. ( Boros, PW; Borsboom, GJ; Enright, PL; Hyatt, RE; Quanjer, PH; Wesolowski, SP, 2010)
"Pulmonary fibrosis is defined by an overgrowth of fibroblasts and extracellular matrix deposition, and results in respiratory dysfunction that is often fatal."	1.36	MRP14 is elevated in the bronchoalveolar lavage fluid of fibrosing interstitial lung diseases. ( Grutters, JC; Kazemier, KM; Korthagen, NM; Nagtegaal, MM; van den Bosch, JM; van Moorsel, CH, 2010)
"Carbon monoxide (CO) is a biologically active molecule produced in the body by the stress-inducible enzyme, heme oxygenase."	1.35	Carbon monoxide modulates alpha-smooth muscle actin and small proline rich-1a expression in fibrosis. ( Alber, S; Choi, AM; Kaminski, N; Lin, L; Morse, D; Watkins, S; Zheng, L; Zhou, Z, 2009)
"Combined pulmonary fibrosis and emphysema (CPFE) is a unique disorder described in several case series of upper lobe emphysema associated with lower lobe fibrosis."	1.35	Heterogeneity in combined pulmonary fibrosis and emphysema. ( Jankowich, MD; Klein, M; Polsky, M; Rounds, S, 2008)
"Idiopathic pulmonary fibrosis is an incurable fibrosing disorder that progresses relentlessly to respiratory failure."	1.33	Carbon monoxide suppresses bleomycin-induced lung fibrosis. ( Alber, S; Choi, AM; Fattman, CL; Greenhill, S; Morse, D; Oury, TD; Song, R; Zhou, Z, 2005)
"In 20 patients with chronic form of hypersensitivity pneumonitis (HP) pulmonary function tests (FEV(1), FVC, DCO) and high resolution computed tomography (HRCT) scans were obtained."	1.33	High-resolution computed tomography in hypersensitivity pneumonitis - correlation with pulmonary function. ( Jastrzebski, D; Kozielski, J; Lubina, M; Wojdała, A; Ziora, D, 2005)
"Idiopathic pulmonary fibrosis is a fatal disease with a variable rate of progression."	1.33	Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. ( Andrei, AC; Colby, TV; Flaherty, KR; Fraley, C; Gross, BH; Kazerooni, EA; Lama, V; Martinez, FJ; Murray, S; Toews, GB; Travis, WD, 2006)
"In idiopathic pulmonary fibrosis, the quantitation of disease severity using pulmonary function tests is often confounded by emphysema."	1.32	Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. ( Colby, TV; Cramer, D; Desai, SR; du Bois, RM; Goh, NS; Hansell, DM; Nicholson, AG; Rubens, MB; Wells, AU, 2003)
"A total of 137 (52 with and 85 without pulmonary fibrosis) had echocardiography and lung function tests within 3 months of their definitive invasive study."	1.32	Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. ( Black, CM; Coghlan, JG; Davar, J; Du Bois, RM; Knight, C; Mukerjee, D; St George, D; Wells, AU, 2004)
"In the BALF and ELF of patients with fibrosing alveolitis, PICP but not PIIINP had significant negative correlations with the specific diffusion coefficient for carbon monoxide (DLCO/ VA)."	1.30	Type III and type I procollagen markers in fibrosing alveolitis. ( Kahlos, K; Kinnula, V; Lähde, S; Lakari, E; Lammi, L; Pääkkö, P; Risteli, J; Ryhänen, L, 1999)
"The amiodarone-treated animals showed a significant reduction in the coefficient of diffusion (kCO) and a significant increase in lung hydroxyproline levels as compared to the control group."	1.29	Amiodarone-induced pulmonary fibrosis in Fischer 344 rats. ( Gairola, CG; Lai, YL; Reinhart, PG, 1996)
"Five patients with cryptogenic fibrosing alveolitis (DLCO ranging from 20-54% predicted normal) exercised for 5 min at a work load equal to 60% of their maximum (45 to 90 watts)."	1.28	DLCO/Q and diffusion limitation at rest and on exercise in patients with interstitial fibrosis. ( Clark, RJ; Hughes, JM; Jones, HA; Lockwood, DN, 1991)
"Fifteen patients with malignant teratoma and twelve with squamous cancer of the head and neck received treatment with bleomycin."	1.27	Role of carbon monoxide diffusing capacity in the early detection of major bleomycin-induced pulmonary toxicity. ( Bell, MR; Gill, PG; Meredith, DJ, 1985)
"Airway obstruction was not associated with smoking habits."	1.27	Clinical, functional and pathological correspondence in early stage idiopathic pulmonary fibrosis: evidence for small airway obstruction 1-2. ( Allard, S; Bernard, C; Martin, RR; Myre, M, 1988)
"In the patients with interstitial pulmonary fibrosis, the influence of the reduced diffusing capacity of the alveolocapillary membrane on the extent of the diffusion disorder was in each case greater than the effects due to the anemia."	1.27	Effect of low hemoglobin levels on the diffusing capacity of the lungs for CO. Investigations in persons with healthy lungs and in patients with interstitial pulmonary fibrosis. ( Petermann, W, 1985)

Research

Studies (92)

Authors

Clinical Trials (9)

Trial Overview

Trial Outcomes

DLCO

Timeframe	Studies, this research(%)	All Research%
pre-1990	36 (39.13)	18.7374
1990's	17 (18.48)	18.2507
2000's	15 (16.30)	29.6817
2010's	20 (21.74)	24.3611
2020's	4 (4.35)	2.80

Authors	Studies
Hu, Y	1
Wang, Q	1
Yu, J	1
Zhou, Q	1
Deng, Y	1
Liu, J	1
Zhang, L	1
Xu, Y	1
Xiong, W	1
Wang, Y	1
Favoino, E	1
Catacchio, G	1
Mininni, A	1
Ruscitti, P	1
Riccieri, V	1
Liakouli, V	1
Corrado, A	1
Navarini, L	1
Ciccia, F	1
Cipriani, P	1
Cantatore, FP	1
Valesini, G	1
Giacomelli, R	1
Perosa, F	1
Goobie, GC	1
Carlsten, C	1
Johannson, KA	1
Khalil, N	1
Marcoux, V	1
Assayag, D	1
Manganas, H	1
Fisher, JH	1
Kolb, MRJ	1
Lindell, KO	1
Fabisiak, JP	1
Chen, X	1
Gibson, KF	1
Zhang, Y	2
Kass, DJ	1
Ryerson, CJ	1
Nouraie, SM	1
Huang, KC	1
Li, JC	1
Wang, SM	1
Cheng, CH	1
Yeh, CH	1
Lin, LS	1
Chiu, HY	1
Chang, CY	1
Chuu, JJ	1
Hashimoto, N	1
Ando, A	1
Iwano, S	1
Sakamoto, K	1
Okachi, S	1
Matsuzaki, A	1
Okada, Y	1
Wakai, K	1
Yokoi, K	1
Hasegawa, Y	1
Trip, P	1
Nossent, EJ	1
de Man, FS	1
van den Berk, IA	1
Boonstra, A	1
Groepenhoff, H	1
Leter, EM	1
Westerhof, N	1
Grünberg, K	1
Bogaard, HJ	1
Vonk-Noordegraaf, A	1
Xu, JF	1
Shen, L	1
Zhang, P	1
Qu, JM	1
Li, HP	1
Nagao, S	1
Taguchi, K	1
Sakai, H	1
Tanaka, R	1
Horinouchi, H	1
Watanabe, H	1
Kobayashi, K	1
Otagiri, M	1
Maruyama, T	1
Inomata, M	1
Ikushima, S	1
Awano, N	1
Kondoh, K	1
Satake, K	1
Masuo, M	1
Kusunoki, Y	1
Moriya, A	1
Kamiya, H	1
Ando, T	1
Yanagawa, N	1
Kumasaka, T	1
Ogura, T	1
Sakai, F	1
Azuma, A	1
Gemma, A	1
Takemura, T	1
Kaushik, SS	1
Freeman, MS	1
Yoon, SW	1
Liljeroth, MG	1
Stiles, JV	1
Roos, JE	1
Foster, W	1
Rackley, CR	1
McAdams, HP	1
Driehuys, B	1
Głodkowska-Mrówka, E	1
Górska, E	1
Ciurzyński, M	1
Stelmaszczyk-Emmel, A	1
Bienias, P	1
Irzyk, K	1
Siwicka, M	1
Lipińska, A	1
Ciepiela, O	1
Pruszczyk, P	1
Demkow, U	1
Tashkin, DP	1
Volkmann, ER	1
Tseng, CH	1
Kim, HJ	1
Goldin, J	1
Clements, P	1
Furst, D	1
Khanna, D	1
Kleerup, E	1
Roth, MD	1
Elashoff, R	1
Özçelik, N	1
Özsu, S	1
Barisione, G	1
Brusasco, C	1
Garlaschi, A	1
Baroffio, M	1
Brusasco, V	1
Enright Md, P	1
Raghu, G	1
Brown, KK	1
Costabel, U	1
Cottin, V	1
du Bois, RM	5
Lasky, JA	1
Thomeer, M	1
Utz, JP	1
Khandker, RK	1
McDermott, L	1
Fatenejad, S	1
Zheng, L	1
Zhou, Z	2
Lin, L	1
Alber, S	2
Watkins, S	1
Kaminski, N	1
Choi, AM	3
Morse, D	2
Xia, DH	1
Xi, L	1
Xv, C	1
Mao, WD	1
Shen, WS	1
Shu, ZQ	1
Yang, HZ	1
Dai, M	1
Boros, PW	1
Enright, PL	1
Quanjer, PH	1
Borsboom, GJ	1
Wesolowski, SP	1
Hyatt, RE	1
Korthagen, NM	1
Nagtegaal, MM	1
van Moorsel, CH	1
Kazemier, KM	1
van den Bosch, JM	1
Grutters, JC	1
Schmidt, SL	1
Nambiar, AM	1
Tayob, N	1
Sundaram, B	1
Han, MK	1
Gross, BH	2
Kazerooni, EA	2
Chughtai, AR	1
Lagstein, A	1
Myers, JL	1
Murray, S	2
Toews, GB	2
Martinez, FJ	2
Flaherty, KR	2
Yanaba, K	1
Asano, Y	1
Tada, Y	1
Sugaya, M	1
Kadono, T	1
Sato, S	1
Chow, S	1
Thomas, PS	1
Malouf, M	1
Yates, DH	1
Peljto, AL	1
Steele, MP	1
Fingerlin, TE	1
Hinchcliff, ME	1
Murphy, E	1
Podlusky, S	1
Carns, M	1
Schwarz, M	1
Varga, J	1
Schwartz, DA	1
Rapti, A	1
Kouranos, V	1
Gialafos, E	1
Aggeli, K	1
Moyssakis, J	1
Kallianos, A	1
Kostopoulos, C	1
Anagnostopoulou, O	1
Sfikakis, PP	1
Wells, AU	4
Tzelepis, GE	1
Henes, JC	1
Horger, M	1
Amberger, C	1
Schmalzing, M	1
Fierlbeck, G	1
Kanz, L	1
Koetter, I	1
Yasuda, H	1
Yamaya, M	1
Yanai, M	1
Ohrui, T	1
Sasaki, H	1
Desai, SR	1
Rubens, MB	2
Goh, NS	1
Cramer, D	2
Nicholson, AG	1
Colby, TV	2
Hansell, DM	2
JOHNSON, RL	1
TAYLOR, HF	1
DEGRAFF, AC	1
WOOLF, CR	1
PEZZAGNO, G	1
CAPODAGLIO, E	1
ORLANDONI, A	1
Yoshioka, Y	1
Saiki, S	1
Tsutsumi-Ishii, Y	1
Koyama, R	1
Hirashima, N	1
Harada, N	1
Yamasaki, S	1
Suda, K	1
Fukuchi, Y	1
Mukerjee, D	1
St George, D	1
Knight, C	1
Davar, J	1
Black, CM	2
Coghlan, JG	1
Song, R	1
Fattman, CL	1
Greenhill, S	1
Oury, TD	1
Ziora, D	1
Jastrzebski, D	1
Lubina, M	1
Wojdała, A	1
Kozielski, J	1
Meissner, HH	1
Soo Hoo, GW	1
Khonsary, SA	1
Mandelkern, M	1
Brown, CV	1
Santiago, SM	1
Ryter, SW	1
Beretta, L	1
Caronni, M	1
Raimondi, M	1
Ponti, A	1
Viscuso, T	1
Origgi, L	1
Scorza, R	1
Andrei, AC	1
Fraley, C	1
Travis, WD	1
Lama, V	1
Emad, A	2
Emad, Y	1
Jankowich, MD	1
Polsky, M	1
Klein, M	1
Rounds, S	1
Luursema, PB	1
Star-Kroesen, MA	1
van der Mark, TW	1
Sleyfer, DT	1
Koops, HS	1
Peset, R	1
Mookherjee, S	1
Ashutosh, K	1
Smulyan, H	1
Vardan, S	1
Warner, R	1
Siemon, G	2
Grosch, W	1
Karmann, F	1
Make, B	1
Miller, A	1
Epler, G	1
Gee, JB	1
Weinberger, SE	1
Johnson, TS	1
Weiss, ST	1
Bankier, AA	1
Kiener, HP	1
Wiesmayr, MN	1
Fleischmann, D	1
Kontrus, M	1
Herold, CJ	1
Graninger, W	1
Hübsch, P	1
Franko, AJ	1
Sharplin, J	1
Dujić, Z	1
Eterović, D	1
Tocilj, J	1
Andjelinović, D	1
Collie, DD	1
Watt, NJ	1
Warren, PM	1
Begara, I	1
Luján, L	1
Reinhart, PG	1
Lai, YL	1
Gairola, CG	1
Frans, A	1
Nemery, B	1
Veriter, C	1
Lacquet, L	1
Francis, C	1
King, AD	1
Singh, SN	1
Fisher, SG	1
Deedwania, PC	1
Rohatgi, P	1
Singh, BN	1
Fletcher, RD	1
Rezaian, GR	1
Yuan, Y	2
Luo, Y	2
Zeng, J	1
He, T	2
Frette, C	1
Jacob, MP	1
Wei, SM	1
Bertrand, JP	1
Laurent, P	1
Kauffmann, F	1
Pham, QT	1
Lammi, L	1
Ryhänen, L	1
Lakari, E	1
Risteli, J	1
Pääkkö, P	1
Kahlos, K	1
Lähde, S	1
Kinnula, V	1
Mukae, H	1
Iiboshi, H	1
Nakazato, M	1
Hiratsuka, T	1
Tokojima, M	1
Abe, K	1
Ashitani, J	1
Kadota, J	1
Matsukura, S	1
Kohno, S	1
Snider, GL	1
Celli, BR	1
Goldstein, RH	1
O'Brien, JJ	1
Lucey, EC	1
Shmidt, NA	1
Pande, JN	1
Guleria, JS	1
Milburn, HJ	1
Prentice, HG	1
Yamaguchi, K	2
Kawai, A	2
Mori, M	2
Asano, K	2
Takasugi, T	2
Umeda, A	2
Kawashiro, T	1
Yokoyama, T	2
Hughes, JM	1
Lockwood, DN	1
Jones, HA	1
Clark, RJ	1
Yin, D	1
Ye, X	1
Bell, MR	1
Meredith, DJ	1
Gill, PG	1
Petermann, W	2
Barth, J	1
Travis, EL	1
Tucker, SL	1
Myre, M	1
Allard, S	1
Bernard, C	1
Martin, RR	1
de Clerck, LS	1
Dequeker, J	1
Francx, L	1
Demedts, M	1
Gulsvik, A	1
Kjelsberg, F	1
Bergmann, A	1
Frøland, SS	1
Rootwelt, K	1
Vale, JR	1
Bréant, J	1
Fleury, MF	1
van Lerberghe, A	1
Maurique, S	1
Frutiger, F	1
Blin, C	1
Baudouin, J	2
Thevenot, C	1
Dezile, G	1
Lavandier, M	2
Homasson, JP	2
Roullier, A	2
Prime, FJ	1
Osaki, Y	1
Makino, M	1
Ostrow, D	1
Cherniack, RM	1
Colp, CR	1
Riker, J	1
Williams, MH	1
Moline, J	1
Bollinelli, R	1
Rouch, Y	1
Fabre, J	1
Carles, P	1
Alves, M	1
Laval, P	1
Feliciano, JM	1
Kleisbauer, JP	1
Poirier, R	1
Lopez-Majano, V	1
Muldoon, BC	1
Turner-Warwick, M	1
Kanagami, H	1
Nagashima, T	1
Saito, T	1
Vandenbergh, E	1
Billiet, L	1
Van de Woestijne, KP	1
Gyselen, A	1
Mährlein, W	1
Renzetti, AD	1
Kobayashi, T	1
Bigler, A	1
Mitchell, MN	1
Jebavý, P	1
Widimský, J	1
Hurych, J	1
Stanĕk, V	1
Weber, J	1
Moret, P	1
Chauvet, M	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Hyperpolarized 129Xe MR Imaging of the Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease[NCT01280994]	Phase 2	445 participants (Anticipated)	Interventional	2011-01-31	Recruiting
Cyclophosphamide Versus Placebo in Scleroderma Lung Study[NCT00004563]	Phase 3	158 participants (Actual)	Interventional	1999-08-31	Completed
Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (Scleroderma Lung Study II)[NCT00883129]	Phase 2	142 participants (Actual)	Interventional	2009-09-30	Completed
Lung Diffusing Capacity for Nitric Oxide and Carbon Monoxide Early After Mild-to-severe COVID-19[NCT04610554]		74 participants (Actual)	Observational	2020-05-14	Completed
Lung Diffusing Capacity for Nitric Oxide as a Marker of Fibrotic Changes in Idiopathic Interstitial Pneumonias[NCT02596841]		60 participants (Actual)	Observational	2013-02-28	Completed
Mechanisms of Pulmonary Diffusion Limitation in Systemic Sclerosis[NCT03601520]		100 participants (Actual)	Observational	2014-03-01	Completed
A Double-blind, Parallel, Placebo-controlled, Randomized Study of the Efficacy and Safety of Etanercept in Patients With Idiopathic Pulmonary Fibrosis.[NCT00063869]	Phase 2	88 participants (Actual)	Interventional		Completed
Effect of Ambroxol on the Inflammatory Markers and Clinical Outcome of Patients With Diabetic Peripheral Neuropathy[NCT05558878]		80 participants (Anticipated)	Interventional	2022-10-01	Not yet recruiting
Validation of the Risk Stratification Score in Idiopathic Pulmonary Fibrosis[NCT02632123]		260 participants (Anticipated)	Observational	2015-12-31	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

diffusing capacity of the lungs for carbon monoxide (NCT00004563)
Timeframe: 12 months

Forced Vital Capacity

Intervention	% of predicted (Mean)
Cylophosphamide	42.8
Placebo	44.3

The primary end point was the forced vital capacity (FVC, expressed as a percentage of the predicted value) at 12 months, after adjustment for the baseline FVC. (NCT00004563)
Timeframe: 12 months

Total Lung Capacity

Intervention	% of predicted (Mean)
Cylophosphamide	66.6
Placebo	65.6

expressed as a percentage of the predicted value (NCT00004563)
Timeframe: 12 months

Fibrosis Score, as Measured by Thoracic High Resolution Computerized Tomography (HRCT)

Intervention	% of predicted (Mean)
Cylophosphamide	70.5
Placebo	64.7

Imaging of the whole lung (WL) is performed using a volumetric high resolution computerized tomography (HRCT) scan, which is then analyzed using a computer algorithm to determine the percentage of overall pixels exhibiting features characteristic for quantitative lung fibrosis (QLF). Higher percentages for QLF-WL therefore represent greater involvement by lung fibrosis. (NCT00883129)
Timeframe: Measured at baseline and Month 24

Forced Vital Capacity (FVC), as a Percent of the Age, Height, Gender, and Ethnicity Adjusted Predicted Value

Intervention	% of lung exhibiting QLF (Mean)
	Baseline	Month 24
Cyclophosphamide Arm	8.91	8.48
Mycophenolate Arm	8.25	7.99

The primary outcome is the course over time from baseline to 24 months for the FVC %-predicted. The FVC %-predicted represents the adjusted volume of air (adjusted as a percentage of the expected normal valued based on the participant's age, height, gender and ethnicity) that can be forcibly exhaled from the lungs after taking the deepest breath possible. The FVC %-predicted is reduced in patients with interstitial lung disease and is used as a measure of lung involvement and disease severity. (NCT00883129)
Timeframe: Measured at study Baseline and Months 3, 6, 12, 15, 18, 21, and 24

Health-related Quality of Life as Measured by the Patient Responses to the Health Assessment Questionnaire Disability Index (HAQ-DI)

Intervention	FVC %-pred (Mean)
	Baseline	Month 3	Month 6	Month 9	Month 12	Month 15	Month 18	Month 21	Month 24
Cyclophosphamide Arm	66.52	67.03	67.86	69.42	69.86	71.94	72.57	72.55	70.15
Mycophenolate Arm	66.52	66.22	68.02	68.11	68.43	69.84	70.57	70.87	69.65

The HAQ-DI asks questions related to 8 activity domains (dressing, arising, eating, walking, hygiene, reach, grip, and common daily activities) with the patient's capacity to carry out each activity scored from 0 to 3. Scores across all domains are averaged and a higher score represents greater disability. (NCT00883129)
Timeframe: Measured at study entry and Months 3, 6, 9, 12, 15, 18, 21, and 24

Single-breath Diffusing Capacity for Carbon Monoxide (DLCO), as a Percent of the Age, Height, Gender, and Ethnicity Adjusted Predicted Value

Intervention	HAQ-DI Total Score (Mean)
	Baseline	Month 3	Month 6	Month 9	Month 12	Month 15	Month 18	Month 21	Month 24
Cyclophosphamide Arm	0.74	0.64	0.58	0.65	0.56	0.62	0.55	0.48	0.57
Mycophenolate Arm	0.71	0.83	0.75	0.66	0.64	0.58	0.55	0.65	0.62

The DLCO is a pulmonary function test that measures the capacity for the lung to carry out gas exchange between the inhaled breath and the pulmonary capillary blood vessels and the DLCO %-predicted represents the DLCO expressed as a percentage of the expected normal valued based on the participant's age, height, gender and ethnicity. The DLCO %-predicted is reduced in patients with interstitial lung disease and is used as a measure of disease severity. (NCT00883129)
Timeframe: Measured at study entry and Months 3, 6, 12, 15, 18, 21, and 24

Skin Involvement, as Measured by the Modified Rodnam Skin Thickness Scores (mRSS)

Intervention	DLCO %-pred (Mean)
	Baseline	Month 3	Month 6	Month 9	Month 12	Month 15	Month 18	Month 21	Month 24
Cyclophosphamide Arm	54.05	51.92	50.87	51.55	53.12	53.62	55.9	54.26	52.90
Mycophenolate Arm	53.99	53.38	54.86	54.13	55.32	57.77	56.62	55.47	55.31

Skin thickness is quantified using the modified Rodnan measurement method (mRSS), with a scale that ranges from 0 (no skin involvement) to a maximum of 51. The reported skin score is determined by a clinical assessment of skin thickness, which is performed by a trained reader, and represents the sum of individual assessments that are made in each of 17 body areas. Each area is given a score in the range of 0-3 (0 = normal; 1= mild thickness; 2 = moderate; 3 = severe thickness). A higher score represents more severe skin involvement. (NCT00883129)
Timeframe: Measured at baseline and Months 3, 6, 9, 12, 15, 18, 21, and 24

Tolerability, as Assessed by the Time to Withdrawal From the Study Drug or Meeting Protocol-defined Criteria for Treatment Failure.

Intervention	mRSS score (Mean)
	Baseline	Month 3	Month 6	Month 9	Month 12	Month 15	Month 18	Month 21	Month 24
Cyclophosphamide Arm	14.04	12.85	11.95	10.61	9.47	9.80	9.87	8.50	7.87
Mycophenolate Arm	15.32	16.03	14.37	14.33	12.45	12.43	11.98	11.22	11.40

The number of participants who remained in the study at the listed time points are reported (NCT00883129)
Timeframe: Continuous assessment from randomization to 24 months

Total Lung Capacity (TLC), as a Percent of the Age, Height, Gender, and Ethnicity Adjusted Predicted Value

Intervention	Participants (Count of Participants)
	Baseline	Month 3	Month 6	Month 9	Month 12	Month 15	Month 18	Month 21	Month 24
Cyclophosphamide Arm	73	64	56	51	46	44	42	39	38
Mycophenolate Arm	69	66	58	55	52	52	49	49	49

The TLC represents the total volume of air within the lung after taking the deepest breath possible and the TLC %-predicted represents the TLC expressed as a percentage of the expected normal valued based on the participant's age, height, gender and ethnicity. The TLC %-predicted is reduced in patients with interstitial lung disease and is used as a measure of disease severity. (NCT00883129)
Timeframe: Measured at study entry and Months 6, 12, 18, and 24

Toxicity, as Measured by Adverse Events, Serious Adverse Events, and Death

Transitional Dyspnea Index Score

Intervention	TLC %-pred (Mean)
	Baseline	Month 6	Month 12	Month 18	Month 24
Cyclophosphamide Arm	65.49	67.39	68.25	69.63	66.97
Mycophenolate Arm	66.16	67.84	67.31	68.50	68.24

Intervention	Participants (Count of Participants)
	Leukopenia (<2.5x10^3 WBC/microliter)	Neutropenia (<1.0x10^3 neutrophils/microliter)	Anemia (Hgb <10 g/dl)	Thrombocytopenia (<100x10^3 platelets/microliter)	Hematuria (>10 RBC/high power field)	Pneumonia	SAE-Total	SAE-related to treatment	Deaths
Cyclophosphamide Arm	30	7	13	4	2	4	22	7	11
Mycophenolate Arm	4	3	8	0	3	5	27	3	5

Change in breathlessness was assessed using the Transitional Dyspnea Index, which compares current symptoms to those at baseline. Total score ranges from - 9 to + 9. The lower the score, the more deterioration in severity of dyspnea. (NCT00883129)
Timeframe: Measured at Months 6, 12, 18, and 24

Article	Year
[A newly-defined entity: combined pulmonary fibrosis and emphysema syndrome]. Tuberkuloz ve toraks, 2015, Volume: 63, Issue:1 Topics: Aged, 80 and over; Carbon Monoxide; Humans; Hypertension, Pulmonary; Lung; Male; Pulmonary Emphysema	2015
Office-based DLCO tests help pulmonologists to make important clinical decisions. Respiratory investigation, 2016, Volume: 54, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Female; Follow-Up Studies; Humans; Lung Diseases, I	2016
Therapeutic applications of carbon monoxide in lung disease. Current opinion in pharmacology, 2006, Volume: 6, Issue:3 Topics: Administration, Inhalation; Animals; Anti-Inflammatory Agents; Apoptosis; Asthma; Bleomycin; Carbon	2006
Single breath diffusing capacity in the industrial setting. Chest, 1982, Volume: 82, Issue:3 Topics: Age Factors; Asbestosis; Carbon Monoxide; Humans; Occupational Diseases; Occupational Medicine; Pulm	1982
[The CO diffusion capacityof the lung in the single breath version (DLCOSB)]. Praxis und Klinik der Pneumologie, 1988, Volume: 42, Issue:8 Topics: Carbon Monoxide; Humans; Pulmonary Diffusing Capacity; Pulmonary Fibrosis	1988
Respiratory function tests for a clinician. B.T.T.A. review, 1973, Volume: 3, Issue:1 Topics: Age Factors; Airway Resistance; Body Height; Bronchitis; Capillaries; Carbon Dioxide; Carbon Monoxid	1973

Article	Year
Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis. Annals of the rheumatic diseases, 2016, Volume: 75, Issue:2 Topics: Adult; Carbon Monoxide; Female; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Multivariate	2016
Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis. Annals of the rheumatic diseases, 2016, Volume: 75, Issue:2 Topics: Adult; Carbon Monoxide; Female; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Multivariate	2016
Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis. Annals of the rheumatic diseases, 2016, Volume: 75, Issue:2 Topics: Adult; Carbon Monoxide; Female; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Multivariate	2016
Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis. Annals of the rheumatic diseases, 2016, Volume: 75, Issue:2 Topics: Adult; Carbon Monoxide; Female; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Multivariate	2016
Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. American journal of respiratory and critical care medicine, 2008, Nov-01, Volume: 178, Issue:9 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Carbon Monoxide; Disease Progression; Double-Blind Me	2008
The protective effects of ambroxol on radiation lung injury and influence on production of transforming growth factor beta1 and tumor necrosis factor alpha. Medical oncology (Northwood, London, England), 2010, Volume: 27, Issue:3 Topics: Adrenal Cortex Hormones; Adult; Aged; Ambroxol; Carbon Monoxide; Female; Free Radical Scavengers; Hu	2010
Increased blood carboxyhaemoglobin concentrations in inflammatory pulmonary diseases. Thorax, 2002, Volume: 57, Issue:9 Topics: Aged; Asthma; Biomarkers; Carbon Monoxide; Carboxyhemoglobin; Female; Humans; Male; Pneumonia; Pulmo	2002
Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis: experience in one centre. Clinical rheumatology, 2007, Volume: 26, Issue:2 Topics: Administration, Oral; Breath Tests; Carbon Monoxide; Cyclophosphamide; Drug Therapy, Combination; Fe	2007
Pulmonary effect of amiodarone in patients with heart failure. The Congestive Heart Failure-Survival Trial of Antiarrhythmic Therapy (CHF-STAT) Investigators (Veterans Affairs Cooperative Study No. 320). Journal of the American College of Cardiology, 1997, Volume: 30, Issue:2 Topics: Aged; Amiodarone; Carbon Monoxide; Heart Failure; Humans; Lung; Lung Diseases, Obstructive; Prospect	1997
High-dose intravenous methylprednisolone pulse therapy as initial treatment in cryptogenic fibrosing alveolitis. A pilot study. Respiration; international review of thoracic diseases, 1986, Volume: 50, Issue:4 Topics: Adult; Aged; Carbon Monoxide; Drug Administration Schedule; Female; Gallium Radioisotopes; Humans; L	1986

Article	Year
Tartrate-resistant acid phosphatase 5 promotes pulmonary fibrosis by modulating β-catenin signaling. Nature communications, 2022, 01-10, Volume: 13, Issue:1 Topics: Animals; beta Catenin; Bleomycin; Carbon Monoxide; Cell Differentiation; Cell Movement; Cell Prolife	2022
Novel biomarker for pulmonary vascular disease in systemic sclerosis patients. Clinical and experimental rheumatology, 2022, Volume: 40, Issue:10 Topics: Biomarkers; Carbon Monoxide; Humans; Hypertension, Pulmonary; Pulmonary Fibrosis; Scleroderma, Syste	2022
Association of Particulate Matter Exposure With Lung Function and Mortality Among Patients With Fibrotic Interstitial Lung Disease. JAMA internal medicine, 2022, 12-01, Volume: 182, Issue:12 Topics: Aged; Air Pollutants; Air Pollution; Ammonium Compounds; Canada; Carbon Monoxide; Cohort Studies; En	2022
The effects of carbon monoxide releasing molecules on paraquat-induced pulmonary interstitial inflammation and fibrosis. Toxicology, 2021, 05-30, Volume: 456 Topics: Animals; Boranes; Carbon Monoxide; Carbonates; Cell Line; Cell Survival; Dose-Response Relationship,	2021
Thin-section computed tomography-determined usual interstitial pneumonia pattern affects the decision-making process for resection in newly diagnosed lung cancer patients: a retrospective study. BMC pulmonary medicine, 2018, Jan-05, Volume: 18, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Clinical Decision-Making; Female; Humans; Lung Dise	2018
Severely reduced diffusion capacity in idiopathic pulmonary arterial hypertension: patient characteristics and treatment responses. The European respiratory journal, 2013, Volume: 42, Issue:6 Topics: Adult; Aged; Carbon Monoxide; Coronary Artery Disease; Familial Primary Pulmonary Hypertension; Fema	2013
Lung biopsy-proved hypersensitivity pneumonitis without known offending antigen: characteristics and follow-up. The clinical respiratory journal, 2014, Volume: 8, Issue:3 Topics: Adult; Aged; Alveolitis, Extrinsic Allergic; Biopsy; Blood Sedimentation; C-Reactive Protein; Carbon	2014
Carbon monoxide-bound hemoglobin-vesicles for the treatment of bleomycin-induced pulmonary fibrosis. Biomaterials, 2014, Volume: 35, Issue:24 Topics: Animals; Bleomycin; Bronchoalveolar Lavage Fluid; Carbon Monoxide; Chemokines; Dose-Response Relatio	2014
An autopsy study of combined pulmonary fibrosis and emphysema: correlations among clinical, radiological, and pathological features. BMC pulmonary medicine, 2014, Jun-28, Volume: 14 Topics: Aged; Aged, 80 and over; Autopsy; Carbon Monoxide; Cysts; Female; Forced Expiratory Volume; Humans;	2014
Measuring diffusion limitation with a perfusion-limited gas--hyperpolarized 129Xe gas-transfer spectroscopy in patients with idiopathic pulmonary fibrosis. Journal of applied physiology (Bethesda, Md. : 1985), 2014, Sep-15, Volume: 117, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Erythrocytes; Female; Healthy Volunteers; Humans; M	2014
Pro- and antiangiogenic markers in patients with pulmonary complications of systemic scleroderma. Respiratory physiology & neurobiology, 2015, Volume: 209 Topics: Adult; Aged; Biomarkers; Blood Pressure; Carbon Monoxide; Enzyme-Linked Immunosorbent Assay; Eye Pro	2015
Lung diffusing capacity for nitric oxide as a marker of fibrotic changes in idiopathic interstitial pneumonias. Journal of applied physiology (Bethesda, Md. : 1985), 2016, 05-01, Volume: 120, Issue:9 Topics: Aged; Biomarkers; Carbon Monoxide; Female; Humans; Idiopathic Interstitial Pneumonias; Lung; Male; N	2016
Lung diffusing capacity for nitric oxide as a marker of fibrotic changes in idiopathic interstitial pneumonias. Journal of applied physiology (Bethesda, Md. : 1985), 2016, 05-01, Volume: 120, Issue:9 Topics: Aged; Biomarkers; Carbon Monoxide; Female; Humans; Idiopathic Interstitial Pneumonias; Lung; Male; N	2016
Lung diffusing capacity for nitric oxide as a marker of fibrotic changes in idiopathic interstitial pneumonias. Journal of applied physiology (Bethesda, Md. : 1985), 2016, 05-01, Volume: 120, Issue:9 Topics: Aged; Biomarkers; Carbon Monoxide; Female; Humans; Idiopathic Interstitial Pneumonias; Lung; Male; N	2016
Lung diffusing capacity for nitric oxide as a marker of fibrotic changes in idiopathic interstitial pneumonias. Journal of applied physiology (Bethesda, Md. : 1985), 2016, 05-01, Volume: 120, Issue:9 Topics: Aged; Biomarkers; Carbon Monoxide; Female; Humans; Idiopathic Interstitial Pneumonias; Lung; Male; N	2016
Lung diffusing capacity for nitric oxide as a marker of fibrotic changes in idiopathic interstitial pneumonias. Journal of applied physiology (Bethesda, Md. : 1985), 2016, 05-01, Volume: 120, Issue:9 Topics: Aged; Biomarkers; Carbon Monoxide; Female; Humans; Idiopathic Interstitial Pneumonias; Lung; Male; N	2016
Lung diffusing capacity for nitric oxide as a marker of fibrotic changes in idiopathic interstitial pneumonias. Journal of applied physiology (Bethesda, Md. : 1985), 2016, 05-01, Volume: 120, Issue:9 Topics: Aged; Biomarkers; Carbon Monoxide; Female; Humans; Idiopathic Interstitial Pneumonias; Lung; Male; N	2016
Lung diffusing capacity for nitric oxide as a marker of fibrotic changes in idiopathic interstitial pneumonias. Journal of applied physiology (Bethesda, Md. : 1985), 2016, 05-01, Volume: 120, Issue:9 Topics: Aged; Biomarkers; Carbon Monoxide; Female; Humans; Idiopathic Interstitial Pneumonias; Lung; Male; N	2016
Lung diffusing capacity for nitric oxide as a marker of fibrotic changes in idiopathic interstitial pneumonias. Journal of applied physiology (Bethesda, Md. : 1985), 2016, 05-01, Volume: 120, Issue:9 Topics: Aged; Biomarkers; Carbon Monoxide; Female; Humans; Idiopathic Interstitial Pneumonias; Lung; Male; N	2016
Lung diffusing capacity for nitric oxide as a marker of fibrotic changes in idiopathic interstitial pneumonias. Journal of applied physiology (Bethesda, Md. : 1985), 2016, 05-01, Volume: 120, Issue:9 Topics: Aged; Biomarkers; Carbon Monoxide; Female; Humans; Idiopathic Interstitial Pneumonias; Lung; Male; N	2016
Carbon monoxide modulates alpha-smooth muscle actin and small proline rich-1a expression in fibrosis. American journal of respiratory cell and molecular biology, 2009, Volume: 41, Issue:1 Topics: Actins; Administration, Inhalation; Animals; Bleomycin; Bone Development; Carbon Monoxide; Cell Deat	2009
Impaired lung compliance and DL,CO but no restrictive ventilatory defect in sarcoidosis. The European respiratory journal, 2010, Volume: 36, Issue:6 Topics: Adult; Carbon Monoxide; Female; Humans; Lung; Lung Compliance; Lung Diseases, Interstitial; Male; Mi	2010
MRP14 is elevated in the bronchoalveolar lavage fluid of fibrosing interstitial lung diseases. Clinical and experimental immunology, 2010, Volume: 161, Issue:2 Topics: Adult; Aged; Biomarkers; Bronchoalveolar Lavage Fluid; Calgranulin B; Carbon Monoxide; Cell Count; F	2010
Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema. The European respiratory journal, 2011, Volume: 38, Issue:1 Topics: Aged; Carbon Monoxide; Diffusion; Emphysema; Female; Fibrosis; Forced Expiratory Volume; Humans; Idi	2011
Clinical significance of serum growth differentiation factor-15 levels in systemic sclerosis: association with disease severity. Modern rheumatology, 2012, Volume: 22, Issue:5 Topics: Adolescent; Adult; Aged; Carbon Monoxide; Child; Disease Progression; Female; Growth Differentiation	2012
Exhaled breath condensate (EBC) biomarkers in pulmonary fibrosis. Journal of breath research, 2012, Volume: 6, Issue:1 Topics: Biomarkers; Breath Tests; Carbon Monoxide; Exhalation; Female; Humans; Hydrogen Peroxide; Lung Disea	2012
The pulmonary fibrosis-associated MUC5B promoter polymorphism does not influence the development of interstitial pneumonia in systemic sclerosis. Chest, 2012, Volume: 142, Issue:6 Topics: Adult; Aged; Carbon Monoxide; Case-Control Studies; Female; Genetic Predisposition to Disease; Genot	2012
Elevated pulmonary arterial systolic pressure in patients with sarcoidosis: prevalence and risk factors. Lung, 2013, Volume: 191, Issue:1 Topics: Adult; Aged; Arterial Pressure; Biomarkers; Carbon Monoxide; Comorbidity; Cross-Sectional Studies; F	2013
Enteric-coated mycophenolate sodium for progressive systemic sclerosis--a prospective open-label study with CT histography for monitoring of pulmonary fibrosis. Clinical rheumatology, 2013, Volume: 32, Issue:5 Topics: Adult; Aged; Carbon Monoxide; Disease Progression; Female; Follow-Up Studies; Humans; Male; Middle A	2013
Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. American journal of respiratory and critical care medicine, 2003, Apr-01, Volume: 167, Issue:7 Topics: Aged; Biopsy; Carbon Monoxide; Female; Follow-Up Studies; Forced Expiratory Volume; Humans; Lung; Ma	2003
FUNCTIONAL SIGNIFICANCE OF A LOW PULMONARY DIFFUSING CAPACITY FOR CARBON MONOXIDE. The Journal of clinical investigation, 1965, Volume: 44 Topics: Altitude; Capillaries; Carbon Monoxide; Cell Membrane Permeability; Oximetry; Physical Exertion; Pul	1965
THE RELATIONSHIPS BETWEEN MINUTE VENTILATION, PULMONARY GAS DIFFUSION AND RESPIRATORY WORK MEASURED SIMULTANEOUSLY DURING A STANDARD EXERCISE TEST. Diseases of the chest, 1965, Volume: 47 Topics: Bronchial Diseases; Bronchiectasis; Bronchitis; Carbon Monoxide; Cystic Fibrosis; Eosinophilic Granu	1965
[The pulmonary diffusion capacity of carbon monoxide studied by the rebreathing method. 3. Results in patients with silicosis and pulmonary fibroses of other etiology]. Giornale di clinica medica, 1961, Volume: 42 Topics: Carbon Monoxide; Humans; Pulmonary Diffusing Capacity; Pulmonary Fibrosis; Respiration; Silicosis	1961
Adult-onset familial pulmonary fibrosis in Japanese brothers. Pathology international, 2004, Volume: 54, Issue:1 Topics: Adult; Carbon Monoxide; Consanguinity; DNA Mutational Analysis; Fatal Outcome; Female; Genetic Predi	2004
Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford, England), 2004, Volume: 43, Issue:4 Topics: Aged; Blood Pressure; Carbon Monoxide; Cardiac Catheterization; Humans; Hypertension, Pulmonary; Mas	2004
Carbon monoxide suppresses bleomycin-induced lung fibrosis. The American journal of pathology, 2005, Volume: 166, Issue:1 Topics: Animals; Bleomycin; Carbon Monoxide; Cell Cycle; Cell Division; Cyclic AMP; Cyclic GMP; Hydroxyproli	2005
High-resolution computed tomography in hypersensitivity pneumonitis - correlation with pulmonary function. Annals of agricultural and environmental medicine : AAEM, 2005, Volume: 12, Issue:1 Topics: Adult; Aged; Alveolitis, Extrinsic Allergic; Carbon Monoxide; Female; Forced Expiratory Volume; Huma	2005
Idiopathic pulmonary fibrosis: evaluation with positron emission tomography. Respiration; international review of thoracic diseases, 2006, Volume: 73, Issue:2 Topics: Aged; Aged, 80 and over; Biopsy; Carbon Monoxide; Fluorodeoxyglucose F18; Humans; Lung; Male; Middle	2006
Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. American journal of respiratory and critical care medicine, 2006, Oct-01, Volume: 174, Issue:7 Topics: Aged; Carbon Monoxide; Exercise Test; Female; Humans; Male; Middle Aged; Multivariate Analysis; Prog	2006
Increased in CD8 T lymphocytes in the BAL fluid of patients with sulfur mustard gas-induced pulmonary fibrosis. Respiratory medicine, 2007, Volume: 101, Issue:4 Topics: Adult; Bronchoalveolar Lavage Fluid; Carbon Monoxide; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; CD8	2007
Heterogeneity in combined pulmonary fibrosis and emphysema. Respiration; international review of thoracic diseases, 2008, Volume: 75, Issue:4 Topics: Aged; Carbon Monoxide; Humans; Lung Volume Measurements; Male; Middle Aged; Pulmonary Diffusing Capa	2008
Bleomycin-induced changes in the carbon monoxide transfer factor of the lungs and its components. The American review of respiratory disease, 1983, Volume: 128, Issue:5 Topics: Adult; Bleomycin; Blood Volume; Breath Tests; Capillary Permeability; Carbon Monoxide; Humans; Lung	1983
Arterial oxygenation and pulmonary function with Saralasin in chronic lung disease. Chest, 1983, Volume: 83, Issue:6 Topics: Adult; Aged; Angiotensin II; Carbon Dioxide; Carbon Monoxide; Cardiac Output; Forced Expiratory Volu	1983
[Lung function parameters in the follow-up of fibrotic lung diseases]. Praxis und Klinik der Pneumologie, 1983, Volume: 37, Issue:9 Topics: Carbon Monoxide; Humans; Partial Pressure; Pulmonary Fibrosis; Respiratory Function Tests; Vital Cap	1983
[Differentiation of CO transfer in blood and membrane components in restrictive ventilation disorders]. Praxis und Klinik der Pneumologie, 1983, Volume: 37 Suppl 1 Topics: Capillary Permeability; Carbon Monoxide; Humans; Pulmonary Diffusing Capacity; Pulmonary Fibrosis; P	1983
Clinical significance of pulmonary function tests. Use and interpretation of the single-breath diffusing capacity. Chest, 1980, Volume: 78, Issue:3 Topics: Capillary Permeability; Carbon Monoxide; Carboxyhemoglobin; Humans; Lung Diseases; Pulmonary Alveoli	1980
Discrete lung involvement in systemic lupus erythematosus: CT assessment. Radiology, 1995, Volume: 196, Issue:3 Topics: Adult; Bronchial Diseases; Carbon Monoxide; Female; Forced Expiratory Volume; Humans; Lung Diseases;	1995
Development of fibrosis after lung irradiation in relation to inflammation and lung function in a mouse strain prone to fibrosis. Radiation research, 1994, Volume: 140, Issue:3 Topics: Animals; Carbon Monoxide; Inflammation; Lung; Male; Mast Cells; Mice; Mice, Inbred Strains; Pulmonar	1994
Increase of pulmonary diffusing capacity in systemic sclerosis. British journal of rheumatology, 1994, Volume: 33, Issue:5 Topics: Adult; Aged; Carbon Monoxide; Female; Humans; Male; Middle Aged; Pulmonary Diffusing Capacity; Pulmo	1994
Effects on lung compliance, lung volume, and single-breath transfer factor for carbon monoxide in sheep with lentivirus-induced lymphoid interstitial pneumonia. American journal of veterinary research, 1993, Volume: 54, Issue:3 Topics: Animals; Body Weight; Carbon Monoxide; Female; Lentivirus; Lentivirus Infections; Lung Compliance; L	1993
Amiodarone-induced pulmonary fibrosis in Fischer 344 rats. Toxicology, 1996, Jun-17, Volume: 110, Issue:1-3 Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Carbon Monoxide; Diffusion; Disease Models, Animal; Fem	1996
Effect of alveolar volume on the interpretation of single breath DLCO. Respiratory medicine, 1997, Volume: 91, Issue:5 Topics: Adult; Blood Gas Analysis; Carbon Monoxide; Female; Humans; Lung Diseases; Male; Pulmonary Alveoli;	1997
Fibrosing alveolitis in systemic sclerosis: indices of lung function in relation to extent of disease on computed tomography. Arthritis and rheumatism, 1997, Volume: 40, Issue:7 Topics: Carbon Monoxide; Female; Humans; Male; Middle Aged; Oxygen; Partial Pressure; Pulmonary Diffusing Ca	1997
The diversity of the effects of sulfur mustard gas inhalation on respiratory system 10 years after a single, heavy exposure: analysis of 197 cases. Chest, 1997, Volume: 112, Issue:3 Topics: Adult; Aged; Airway Obstruction; Asthma; Biopsy; Bronchiectasis; Bronchitis; Bronchoscopy; Carbon Mo	1997
[Diagnostic value of exercise diffusion capacity test on diffuse pulmonary fibrosis]. Hua xi yi ke da xue xue bao = Journal of West China University of Medical Sciences = Huaxi yike daxue xuebao, 1996, Volume: 27, Issue:2 Topics: Adult; Carbon Monoxide; Exercise Test; Female; Humans; Lung; Lung Diseases, Interstitial; Lung Disea	1996
Relationship of serum elastin peptide level to single breath transfer factor for carbon monoxide in French coal miners. Thorax, 1997, Volume: 52, Issue:12 Topics: Adult; Carbon Monoxide; Coal Mining; Cohort Studies; Elastin; Humans; Lung; Male; Middle Aged; Occup	1997
Type III and type I procollagen markers in fibrosing alveolitis. American journal of respiratory and critical care medicine, 1999, Volume: 159, Issue:3 Topics: Biomarkers; Bronchoalveolar Lavage Fluid; Carbon Monoxide; Epithelium; Female; Follow-Up Studies; Hu	1999
Raised plasma concentrations of alpha-defensins in patients with idiopathic pulmonary fibrosis. Thorax, 2002, Volume: 57, Issue:7 Topics: alpha-Defensins; Bronchoalveolar Lavage Fluid; Carbon Monoxide; Female; Forced Expiratory Volume; Gl	2002
Chronic interstitial pulmonary fibrosis produced in hamsters by endotracheal bleomycin. Lung volumes, volume-pressure relations, carbon monoxide uptake, and arterial blood gas studied. The American review of respiratory disease, 1978, Volume: 117, Issue:2 Topics: Animals; Bleomycin; Blood Gas Analysis; Carbon Monoxide; Cricetinae; Disease Models, Animal; Lung; L	1978
[Effect of moderate cooling of the body on the retention of slightly fibrogenic dust in the lungs of rats]. Gigiena truda i professional'nye zabolevaniia, 1979, Issue:5 Topics: Animals; Carbon Monoxide; Dust; Hypothermia; Lung; Male; Nitrogen Oxides; Phagocytosis; Pulmonary Fi	1979
Comparison of single breath and steady state methods for the measurement of pulmonary diffusing capacity for carbon monoxide in non-homogeneous lungs. Respiration; international review of thoracic diseases, 1978, Volume: 36, Issue:3 Topics: Carbon Monoxide; Diffusion; Humans; Mathematics; Models, Biological; Pulmonary Fibrosis; Respiration	1978
Can lung function measurements be used to predict which patients will be at risk of developing interstitial pneumonitis after bone marrow transplantation? Thorax, 1992, Volume: 47, Issue:6 Topics: Adolescent; Adult; Blood Gas Analysis; Bone Marrow Transplantation; Carbon Monoxide; Child; Forced E	1992
Distribution of ventilation and of diffusing capacity to perfusion in the lung. Respiration physiology, 1991, Volume: 86, Issue:2 Topics: Animals; Carbon Dioxide; Carbon Monoxide; Diffusion; Humans; Lung; Mathematics; Oxygen; Pulmonary Fi	1991
Continuous distributions of ventilation and gas conductance to perfusion in the lungs. Advances in experimental medicine and biology, 1990, Volume: 277 Topics: Carbon Dioxide; Carbon Monoxide; Humans; Models, Biological; Noble Gases; Oxygen; Pulmonary Diffusin	1990
DLCO/Q and diffusion limitation at rest and on exercise in patients with interstitial fibrosis. Respiration physiology, 1991, Volume: 83, Issue:2 Topics: Adult; Aged; Carbon Monoxide; Exercise; Female; Humans; Lung; Lung Volume Measurements; Male; Middle	1991
[Argon replacing helium in measurement of pulmonary carbon monoxide diffusing capacity, its normal value and clinical application]. Hua xi yi ke da xue xue bao = Journal of West China University of Medical Sciences = Huaxi yike daxue xuebao, 1990, Volume: 21, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Argon; Carbon Monoxide; Chromatography, Gas; Female; Hel	1990
Role of carbon monoxide diffusing capacity in the early detection of major bleomycin-induced pulmonary toxicity. Australian and New Zealand journal of medicine, 1985, Volume: 15, Issue:2 Topics: Adolescent; Adult; Bleomycin; Breath Tests; Carbon Monoxide; Carcinoma, Squamous Cell; Female; Head	1985
The relationship between functional assays of radiation response in the lung and target cell depletion. The British journal of cancer. Supplement, 1986, Volume: 7 Topics: Animals; Carbon Dioxide; Carbon Monoxide; Cell Survival; Dose-Response Relationship, Radiation; Lung	1986
Clinical, functional and pathological correspondence in early stage idiopathic pulmonary fibrosis: evidence for small airway obstruction 1-2. Respiration; international review of thoracic diseases, 1988, Volume: 53, Issue:3 Topics: Adult; Airway Obstruction; Bronchi; Bronchial Provocation Tests; Carbon Monoxide; Female; Forced Exp	1988
D-penicillamine therapy and interstitial lung disease in scleroderma. A long-term followup study. Arthritis and rheumatism, 1987, Volume: 30, Issue:6 Topics: Carbon Monoxide; Diffusion; Follow-Up Studies; Humans; Lung; Penicillamine; Pulmonary Fibrosis; Resp	1987
Effect of low hemoglobin levels on the diffusing capacity of the lungs for CO. Investigations in persons with healthy lungs and in patients with interstitial pulmonary fibrosis. Respiration; international review of thoracic diseases, 1985, Volume: 47, Issue:1 Topics: Adult; Aged; Anemia; Carbon Monoxide; Female; Hemoglobins; Humans; Male; Middle Aged; Pulmonary Diff	1985
[Steady-state carbon monoxide transfer during progressive muscular exercise in patients. Relation to PaO2. Value of specific VCO]. Revue de pneumologie clinique, 1985, Volume: 41, Issue:2 Topics: Aging; Carbon Monoxide; Humans; Hypoxia; Lung Diseases; Lung Diseases, Obstructive; Male; Middle Age	1985
[Pulmonary fibrosis by hard metals. Functional and immunological study of 4 cases]. Revue de l'Institut d'hygiene des mines, 1974, Volume: 29, Issue:3 Topics: Adult; Aged; Carbon; Carbon Monoxide; Cobalt; DNA; Dyspnea; Humans; Immunoglobulin E; Immunologic De	1974
[Limitation of clinical examinations. V. Pulmonary diffusing capacity]. Kokyu to junkan. Respiration & circulation, 1972, Volume: 20, Issue:8 Topics: Capillaries; Carbon Monoxide; Hemoglobins; Humans; Lung Diseases, Obstructive; Methods; Pulmonary Al	1972
Resistance to airflow in patients with diffuse interstitial lung disease. The American review of respiratory disease, 1973, Volume: 108, Issue:2 Topics: Aged; Airway Resistance; Carbon Monoxide; Female; Humans; Lung; Lung Compliance; Male; Middle Aged;	1973
Serial changes in scleroderma and idiopathic interstitial lung disease. Archives of internal medicine, 1973, Volume: 132, Issue:4 Topics: Adult; Aged; Arteries; Carbon Monoxide; Cyclophosphamide; Female; Humans; Lung Compliance; Male; Mer	1973
[Determination of the membrane factor in alveolo-capillary exchanges. Clinical application]. Le Poumon et le coeur, 1973, Volume: 29, Issue:2 Topics: Capillaries; Capillary Permeability; Carbon Monoxide; Diffusion; Humans; Membranes; Methods; Models,	1973
[Pulmonary exchanges in slowly developing diffuse interstitial fibrosis. Radio-functional and anatomo-functional correlations. Role of spirography, gas determination and ductances in the respiratory balance]. Le Poumon et le coeur, 1973, Volume: 29, Issue:5 Topics: Adult; Biopsy; Blood Gas Analysis; Capillaries; Carbon Monoxide; Factor Analysis, Statistical; Femal	1973
[Value of functional respiratory exploration in the course of diffuse interstitial pulmonary fibrosis]. Le Poumon et le coeur, 1973, Volume: 29, Issue:5 Topics: Adult; Aged; Apnea; Carbon Monoxide; Female; Humans; Male; Methods; Middle Aged; Prognosis; Pulmonar	1973
Diffusing capacity in pulmonary fibrosis, sarcoidosis and bronchogenic carcinoma. Respiration; international review of thoracic diseases, 1972, Volume: 29, Issue:1 Topics: Bronchial Neoplasms; Bronchodilator Agents; Carbon Monoxide; Carcinoma, Bronchogenic; Humans; Pulmon	1972
Lung function studies in asbestos workers. British journal of diseases of the chest, 1972, Volume: 66, Issue:2 Topics: Adult; Aged; Airway Obstruction; Asbestosis; Bronchitis; Carbon Monoxide; Chronic Disease; Female; H	1972
[Pulmonary diffusing capacity and regional pulmonary function]. Iryo, 1971, Volume: 25, Issue:7 Topics: Adolescent; Adult; Aged; Asthma; Carbon Monoxide; Chronic Disease; Female; Heart Septal Defects, Atr	1971
Relation between single-breath diffusing capacity and arterial blood gases in chronic obstructive lung disease. Scandinavian journal of respiratory diseases, 1968, Volume: 49, Issue:2 Topics: Adult; Aged; Carbon Monoxide; Chronic Disease; Diffusion; Female; Granuloma; Humans; Hypoxia; Lung D	1968
[Diagnostic value of the static compliance and carbon monoxide diffusion capacity in the verification of a pulmonary fibrosis associated with silicoses]. Zeitschrift fur Erkrankungen der Atmungsorgane mit Folia bronchologica, 1971, Volume: 135, Issue:2 Topics: Anthracosilicosis; Carbon Monoxide; Humans; Lung Compliance; Pulmonary Diffusing Capacity; Pulmonary	1971
Regional ventilation and perfusion in silicosis and in the alveolar-capillary block syndrome. The American journal of medicine, 1970, Volume: 49, Issue:1 Topics: Adult; Aged; Arthritis, Rheumatoid; Body Surface Area; Bronchitis; Capillaries; Carbon Dioxide; Carb	1970
Relationship between orthostatic changes of pulmonary diffusing capacity and haemodynamics of lesser circulation. Respiration; international review of thoracic diseases, 1971, Volume: 28, Issue:2 Topics: Blood Pressure; Carbon Monoxide; Cardiac Output; Catheterization; Diffusion; Heart; Heart Rate; Hemo	1971
[Utility of the diffusion test with carbon monoxide in functional exploration of the lung]. Helvetica medica acta, 1967, Volume: 34, Issue:1 Topics: Age Factors; Asthma; Bronchitis; Carbon Monoxide; Emphysema; Humans; Lung Neoplasms; Pulmonary Fibro	1967

carbon monoxide and Alveolitis, Fibrosing